C12Y 207/0102
Adenosine kinase
Official title: Adenosine kinase (2.7.1.20)
C12Y207/0102 (Adenosine kinase) appears on 6 US grants and 16 published applications in this corpus.
Search patents in C12Y- Granted patents
- 6
- Published applications
- 16
- Assignees
- 13
- Inventors
- 45
- Latest grant
- 18 Feb 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 0 | 2 |
| 2020 | 1 | 0 |
| 2021 | 1 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 4 |
| 2025 | 1 | 2 |
| 2026 | 0 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Cell-free expression system having novel inorganic polyphosphate-based energy regeneration18 Feb 2025US 12,227,778 B2Nature's Toolbox, Inc.
- Cell-free expression system having novel inorganic polyphosphate-based energy regeneration5 Oct 2021US 11,136,586 B2NTxBio, LLC
- Compositions for preventing or treating sepsis or septic shock compromising ADK protein as active ingredient11 Aug 2020US 10,736,944 B2Konkuk University Glocal Industry-Academic Collaboration Foundation
- Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent14 Oct 1997US 5,676,978 AAmira, Inc.
- Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated28 Jun 1994US 5,324,731 AAmira, Inc.
- Methods for the Production of Tryptophan Derivatives23 Jul 2026US 2026/0209808 A1Natural MedTech Pty Ltd
- Method for producing methyl compound2 Jul 2026US 2026/0185132 A1Mitsubishi Chemical Corporation
- Method for producing methyl compound7 May 2026US 2026/0125722 A1Mitsubishi Chemical Corporation
- Antisense oligonucleotides targeting adenosine kinase1 May 2025US 2025/0136990 A1NEUmiRNA Therapeutics Aps
- Engineered adenosine kinase variants17 Apr 2025US 2025/0122486 A1Codexis, Inc.
Most cited
By later US patents
- Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated39US 5,324,731 AAmira, Inc. · 1994
- Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent24US 5,676,978 AAmira, Inc. · 1997
- Creatine analogs having antiviral activity22US 5,321,030 AAmira, Inc. · 1994